Inventia Healthcare recalls over 13,000 bottles of chlorthalidone tablets due to failed dissolution tests
Just the facts

Inventia Healthcare recalls over 13,000 bottles of chlorthalidone tablets due to failed dissolution tests

Summary

Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of 25 mg chlorthalidone tablets after FDA testing showed they did not meet dissolution standards, marking the company's second Class II recall this year.

Inventia Healthcare Limited announced a voluntary recall of 13,567 bottles of 25 mg chlorthalidone tablets (batch numbers RISA24001, RISB24002, RISA24002) after FDA testing indicated the tablets failed dissolution testing, which assesses how a drug dissolves in the body. The recall, classified as Class II, follows an earlier recall of 11,460 bottles of the same medication earlier in June.

The FDA defines a Class II recall as a situation where use of the product could cause temporary or medically reversible health effects, while the likelihood of serious adverse consequences is considered remote. Dissolution failure means the active ingredient may not be absorbed properly, potentially reducing the drug’s effectiveness in lowering blood pressure.

Patients currently taking the recalled tablets are advised to consult their healthcare providers before making any changes to their medication regimen. The FDA notes that, for Class II recalls, consumers may generally continue using the product unless the manufacturer issues different instructions.

"Consumers can generally continue taking the medicine unless the recalling company provides other instructions," the FDA states.

Chlorthalidone is a diuretic used to help control high blood pressure by promoting the excretion of excess salt and water. Reduced efficacy could increase the risk of complications such as stroke or heart attack over time. Patients can verify whether their medication is affected by checking the batch numbers against the FDA recall listings D-0852-2026 and D-0610-2026.

Keep reading — for free

Create a free account to follow the news. No card required.